IBD Market Snapshot: Changes Ahead, But Current Biologics Are Formidable Competitors

Zeposia Adds A Second Oral Advanced Therapy

The ulcerative colitis and Crohn’s disease landscapes may shift soon but new drugs will compete with entrenched blockbusters, including Humira, Stelara and Entyvio, with biosimilars on the way.

Pain in human intestines, bowel concept — The IBD market is crowded but with room for improvement • Source: Shutterstock

Inflammatory bowel disease is an increasingly crowded market with an influx of novel therapies recently launched or nearing approvals. The good news for up-and-coming treatments is that established products leave a lot of room for improvement. The bad news is that novel drugs for ulcerative colitis and Crohn’s disease will compete with entrenched therapeutics, such as AbbVie Inc.’s TNF inhibitor Humira (adalimumab) and Johnson & Johnson’s interleukin-12 (IL-12)/IL-23 inhibitor Stelara (ustekinumab), for which biosimilars will be available in the next one to two years.

While anti-TNF biologics and other advanced therapies are the standard of care after conventional front-line therapeutics for ulcerative colitis (UC) and Crohn’s disease (CD) patients, Humira biosimilars could make for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

28 May 2025

• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

Pipeline Watch: 12 Approvals And 26 Phase III Readouts

26 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

22 May 2025

• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.